^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Esophageal and Esophagogastric Junction Cancers: Useful in Certain Circumstances...Pembrolizumab for TMB high (≥10 mutations/megabase) tumors…
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Source:
Title:
Effect of multi-omics analysis on tumor ecosystem during neoadjuvant dose-limiting chemotherapy combination with sequential PD-1 blockade for patients with esophageal cancer.
Published date:
05/25/2023
Excerpt:
A study on 23 enrolled patients with esophageal cancer who received 2 cycles of neoadjuvant treatment of dose-limiting chemotherapy combined with sequential pembrolizumab...After neoadjuvant therapy, the percentage of patients with a pathological major response (MPR) was 39.1% (9/23), consisting of 21.7% (5/23) completed pathological response (cPR)...Tumor mutational burden (TMB) was higher in the MPR group than in the non-MPR group at baseline...Additionally, TMB, CD8+ T cells, and Treg cells are associated with clinical benefits during treatment.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2023.41.16_suppl.e16085
